GSK (
GSK.L) has been an extremely good investment for us. Aeryn (the AI engine) has made good predictions and a good and healthy dividend yield has seen us get some great profits for our clients. The news that GSK has acquired the full rights to develop, manufacture, and market COVID-19 and influenza vaccines from Germany's CureVac is some further good news.
GSK, the UK’s second-largest pharmaceutical company, is paying €400 million (£339 million, $430 million) upfront, with the potential for an additional €1.05 billion to the biotech firm CureVac. The two companies have restructured their existing collaboration into a new licensing agreement.
Since 2020, GSK and CureVac have collaborated to develop mRNA vaccines for infectious diseases. GSK will now take over CureVac's leading experimental vaccines targeting infections, including seasonal flu and ...
Sign up to read the entire article. It's Free and Simple to sign up!
We are offering a
FREE 30 day trial which includes full access to the following services here at investorAi.
You only need an email address to sign up! You will NOT be billed at the end of your trial unless you wish to begin a subscription.